Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Hydroxocobalamin Acetate

What is Hydroxocobalamin Acetate?

CAS No: 22465-48-1

Hydroxocobalamin Acetate is the salt form of its parent API, engineered to achieve a target aqueous solubility and dissolution profile that ensures consistent oral bioavailability across the patient population. The stoichiometry of API to counter-ion, defined in the salt’s molecular formula, determines the dose equivalent and the appropriate molecular weight correction applied when converting the PDE value to a cleaning validation maximum allowable carryover expressed in mass of salt per unit equipment surface area or per unit rinse volume.

The intraspecies uncertainty factor F2 for Hydroxocobalamin Acetate covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients with organ impairment affecting Hydroxocobalamin Acetate elimination, and patients receiving CY

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Hydroxocobalamin Acetate is the acetate form of hydroxocobalamin, a naturally occurring form of vitamin B12 that is used in the treatment of vitamin B12 deficiency. A documented assessment can place its handling and potential occupational exposure in context for manufacturers.

A PDE or ADE sets a health-based limit on daily exposure to Hydroxocobalamin Acetate from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

A toxicological assessment characterizes the potential health hazards of Hydroxocobalamin Acetate using the available data. It supports scientifically justified exposure limits, helps manufacturers choose proportionate handling and containment measures, and gives a documented basis for protecting workers and preventing cross-contamination in shared facilities.

Where therapeutic or clinical dose information exists, it can support the assessment, for example by indicating doses at which effects are seen in people. It is weighed with non-clinical data and adjusted for the exposure scenario, since doses given to patients are not the same as unintended residual or workplace exposure to Hydroxocobalamin Acetate.

A PDE is a health-based limit on the daily amount of Hydroxocobalamin Acetate that could be carried over into another product and taken by patients. An OEL is a workplace airborne limit intended to protect workers over a working lifetime. They serve different purposes and use different exposure assumptions, so they are assessed separately even when drawn from the same toxicological data.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Hydroxocobalamin Acetate in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Yes, it can. Fine powders and dusty solids may be inhaled more easily, liquids and solutions can raise skin contact or splash considerations, and granulated or compacted material may generate less dust. The assessment should state the form of Hydroxocobalamin Acetate considered, because the form influences likely routes of exposure and the controls that are proportionate.

Not usually. An OEB is a hazard-based category that guides handling and containment when a compound-specific OEL is not available, while an OEL is a numerical airborne limit based on a detailed review of the evidence. Where an OEL can be justified for Hydroxocobalamin Acetate, it normally provides a more specific benchmark, and the band can still support the control strategy.

An assessment of Hydroxocobalamin Acetate should be reviewed when new toxicological or clinical data become available, when the way the material is used or handled changes, or when relevant guidance is updated. A periodic review keeps the documented rationale current and helps confirm that exposure limits and handling recommendations remain appropriate for actual processing conditions.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Hydroxocobalamin Acetate to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo